National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
RIKILT, Wageningen University & Research, Wageningen, The Netherlands.
Part Fibre Toxicol. 2018 Apr 11;15(1):15. doi: 10.1186/s12989-018-0251-7.
Titanium dioxide (TiO) is produced at high volumes and applied in many consumer and food products. Recent toxicokinetic modelling indicated the potential of TiO to accumulate in human liver and spleen upon daily oral exposure, which is not routinely investigated in chronic animal studies. A health risk from nanosized TiO particle consumption could not be excluded then.
Here we show the first quantification of both total titanium (Ti) and TiO particles in 15 post-mortem human livers and spleens. These low-level analyses were enabled by the use of fully validated (single particle) inductively coupled plasma high resolution mass spectrometry ((sp)ICP-HRMS) detection methods for total Ti and TiO particles. The presence of TiO in the particles in tissues was confirmed by Scanning Electron Microscopy with energy dispersive X-ray spectrometry.
These results prove that TiO particles are present in human liver and spleen, with ≥24% of nanosize (< 100 nm). The levels are below the doses regarded as safe in animals, but half are above the dose that is deemed safe for liver damage in humans when taking into account several commonly applied uncertainty factors. With these new and unique human data, we remain with the conclusion that health risks due to oral exposure to TiO cannot be excluded.
二氧化钛(TiO)的产量很高,广泛应用于许多消费品和食品产品中。最近的毒代动力学模型表明,TiO 可能会在日常口服暴露时在人体肝脏和脾脏中积累,而这在慢性动物研究中通常不会进行调查。那么,从纳米 TiO 颗粒摄入的健康风险就不能被排除。
在这里,我们首次定量分析了 15 例人死后肝脏和脾脏中的总钛(Ti)和 TiO 颗粒。这些低水平的分析是通过使用完全验证的(单颗粒)电感耦合等离子体质谱高分辨率质谱(spICP-HRMS)检测方法来实现的,用于检测总 Ti 和 TiO 颗粒。通过扫描电子显微镜与能量色散 X 射线光谱法确认了组织中 TiO 颗粒的存在。
这些结果证明了 TiO 颗粒存在于人体肝脏和脾脏中,其中纳米尺寸(<100nm)的颗粒占≥24%。这些水平低于动物安全剂量,但如果考虑到几种常用的不确定性因素,这些水平是人类肝脏损伤安全剂量的一半以上。有了这些新的和独特的人类数据,我们仍然认为不能排除因口服暴露于 TiO 而产生的健康风险。